Foundation Medicine Launches FoundationOne®PGx in Partnership with Fulgent Genetics
Foundation Medicine has launched FoundationOne®PGx, a pharmacogenetic offering aimed at guiding cancer therapy selection and dosing strategies to enhance patient care. This initiative is a result of an expanded partnership with Fulgent Genetics.
BOSTON & EL MONTE, Calif.–(BUSINESS WIRE)–FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care